Economics
fiscal profligacy (Government spending as a percent of GDP is too high and the looming explosion in entitlement expenditures will make it worse. There is no good solution save spending discipline.). In the interest of being fair and balanced:
Politics
Domestic
I have been attempting to avoid political commentary, but this editorial on Ahmadinejab’s
http://author.nationalreview.com/latest/?q=MjE5NQ==
International War Against Radical Islam
I have said this repeatedly: the Saudis are not our friends:
http://ibdeditorial.com/IBDArticles.aspx?id=275697948158759
The Market
Technical
Fundamental
I mentioned Johnson and Johnson yesterday as a high quality company but one whose stock has lagged in the bifurcated Market in which we find ourselves. Another name I really like in the healthcare area is Abbott Labs.
Abbott Laboratories is a manufacturer of drugs, diagnostic tests, intravenous solutions, laboratory and hospital instruments, prepared infant formulas and nutritional products. The company has several new drugs in its pipeline which should allow it to continue its historical 10-11% annual earnings and dividend growth. Indeed, growth in pharmaceutical sales this year have jumped dramatically as a result of its new drug, Humira, used for the treatment of rheumatoid arthritis, psoriatic arthritis and Cronins’ disease. Abbott earns 25% return on equity and has a debt to equity ratio of only 21%.
EPS: 2006 $2.52, 2007 $2.82, 2008 $3.25; DVD: $1.30 YLD 2.5%
http://finance.yahoo.com/q?s=ABT
News on Stocks in Our Portfolios
A positive write up on Emerson Electric (Dividend Growth Portfolio):
http://www.zacks.com/rank/zcommentary/?id=5997
EPS: 2006 $.75, 2007 $.95, 2008 $1.10; DVD: $.34 YLD 2.4%
http://finance.yahoo.com/q?s=RMCF
More Cash in Investors’ Hands
No comments:
Post a Comment